Zacks Research Issues Negative Outlook for Amgen Earnings

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Zacks Research lowered their Q1 2025 earnings estimates for shares of Amgen in a research report issued on Friday, October 25th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $4.69 for the quarter, down from their previous estimate of $4.79. The consensus estimate for Amgen’s current full-year earnings is $19.49 per share. Zacks Research also issued estimates for Amgen’s Q2 2025 earnings at $5.07 EPS, Q1 2026 earnings at $4.84 EPS, Q2 2026 earnings at $5.20 EPS, Q3 2026 earnings at $5.27 EPS and FY2026 earnings at $20.75 EPS.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the previous year, the business earned $5.00 earnings per share.

A number of other research firms have also recently issued reports on AMGN. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and raised their target price for the stock from $320.00 to $333.00 in a research note on Monday, October 14th. Robert W. Baird restated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research report on Wednesday, September 25th. Dbs Bank upgraded Amgen to a “strong-buy” rating in a report on Monday, September 16th. Oppenheimer reiterated an “outperform” rating and set a $380.00 target price on shares of Amgen in a research note on Wednesday, August 7th. Finally, Barclays boosted their price target on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $332.55.

Amgen Trading Up 0.1 %

AMGN stock opened at $317.17 on Monday. Amgen has a one year low of $249.70 and a one year high of $346.85. The stock has a market cap of $170.14 billion, a price-to-earnings ratio of 45.31, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a fifty day moving average price of $325.27 and a two-hundred day moving average price of $314.44. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AMGN. Strategic Financial Concepts LLC acquired a new position in Amgen during the 2nd quarter worth approximately $26,000. Hershey Financial Advisers LLC acquired a new position in shares of Amgen during the second quarter worth $30,000. nVerses Capital LLC bought a new position in shares of Amgen in the 2nd quarter valued at $31,000. Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen during the 2nd quarter valued at $33,000. Finally, Matrix Trust Co bought a new stake in Amgen during the 3rd quarter worth $36,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is presently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.